MANNKIND CORP Increase (Decrease) in Deferred Revenue
MANNKIND CORP (MNKD) reported Increase (Decrease) in Deferred Revenue of -$381.00 thousand for the 12-month period ending 2017-12-31, per its 10-K filed 2018-02-27.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredRevenue · last filed 2018-11-01
- MANNKIND CORP increase (decrease) in deferred revenue for the quarter ending 2017-12-31 was $17.00K, a 98.79% decline year-over-year.
- MANNKIND CORP increase (decrease) in deferred revenue for the quarter ending 2017-09-30 was $429.00K.
- MANNKIND CORP increase (decrease) in deferred revenue for the quarter ending 2017-06-30 was $748.00K, a 91.87% decline year-over-year.
- MANNKIND CORP increase (decrease) in deferred revenue for the quarter ending 2017-03-31 was -$1.57M, a 989.83% decline year-over-year.
- MANNKIND CORP increase (decrease) in deferred revenue for fiscal 2017 was -$381.00K, a 111.14% decline from fiscal 2016.
- MANNKIND CORP increase (decrease) in deferred revenue for fiscal 2016 was $3.42M, a 79.97% decline from fiscal 2015.
- MANNKIND CORP increase (decrease) in deferred revenue for fiscal 2015 was $17.07M.
| Period end | Increase (Decrease) in Deferred Revenue 3 month | Increase (Decrease) in Deferred Revenue 6 month | Increase (Decrease) in Deferred Revenue 6 month as first filed | Increase (Decrease) in Deferred Revenue 9 month | Increase (Decrease) in Deferred Revenue 12 month | Increase (Decrease) in Deferred Revenue 283 month |
|---|---|---|---|---|---|---|
| 2017-12-31 | $17.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | $446.00K derived: sum of 2 quarters · filed 2018-11-01 | $1.19M derived: sum of 3 quarters · filed 2018-11-01 | -$381.00K 10-K · filed 2018-02-27 | ||
| 2017-09-30 | $429.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01 | $1.18M derived: sum of 2 quarters · filed 2018-11-01 | -$398.00K 10-Q · filed 2018-11-01 | $1.01M derived: sum of 4 quarters · filed 2018-11-01 | ||
| 2017-06-30 | $748.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-02 | -$827.00K 10-Q · filed 2018-08-02 | $578.00K derived: sum of 3 quarters · filed 2018-08-02 | -$6.79M derived: sum of 4 quarters · filed 2018-08-02 | ||
| 2017-03-31 | -$1.57M 10-Q · filed 2018-05-09 | -$170.00K derived: sum of 2 quarters · filed 2018-05-09 | -$7.54M derived: sum of 3 quarters · filed 2018-05-09 | $1.67M derived: sum of 4 quarters · filed 2018-05-09 | ||
| 2016-12-31 | $1.41M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | -$5.96M derived: sum of 2 quarters · filed 2018-02-27 | $3.24M derived: sum of 3 quarters · filed 2018-02-27 | $3.42M 10-K · filed 2018-02-27 | ||
| 2016-09-30 | -$7.37M derived: 10-Q 9 month − 10-Q/A 6 month · filed 2017-11-07 | $1.84M derived: sum of 2 quarters · filed 2017-11-07 | $2.01M 10-Q · filed 2017-11-07 | $2.04M derived: sum of 4 quarters · filed 2017-11-07 | ||
| 2016-06-30 | $9.20M derived: 10-Q/A 6 month − 10-Q 3 month · filed 2016-08-10 | $9.38M 10-Q/A · filed 2016-08-10 | $177.00K 10-Q · filed 2016-08-09 | $9.41M derived: sum of 3 quarters · filed 2016-08-10 | $13.48M derived: sum of 4 quarters · filed 2016-08-10 | |
| 2016-03-31 | $177.00K 10-Q · filed 2016-05-09 | $206.00K derived: sum of 2 quarters · filed 2016-05-09 | $4.28M derived: sum of 3 quarters · filed 2016-05-09 | $10.19M derived: sum of 4 quarters · filed 2016-08-10 | ||
| 2015-12-31 | $29.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-15 | $4.10M derived: sum of 2 quarters · filed 2016-03-15 | $10.02M derived: sum of 3 quarters · filed 2016-08-10 | $17.07M 10-K · filed 2016-03-15 | ||
| 2015-09-30 | $4.07M derived: 10-Q 9 month − 10-Q/A 6 month · filed 2015-11-09 | $9.99M derived: sum of 2 quarters · filed 2016-08-10 | $17.04M 10-Q · filed 2015-11-09 | |||
| 2015-06-30 | $5.92M derived: 10-Q/A 6 month − 10-Q 3 month · filed 2016-08-10 | $12.97M 10-Q/A · filed 2016-08-10 | ||||
| 2015-03-31 | $7.05M 10-Q · filed 2016-05-09 | |||||
| 2014-09-30 | $150.00M 10-Q · filed 2014-11-10 | $150.00M 10-Q · filed 2014-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |